• Mesa Laboratories posted net income of USD 6.71 million, swinging to profit from a loss in fiscal 2026.
• Revenue rose 3.4% to USD 249.13 million, led by Sterilization and Disinfection Control up 8.7% to USD 101.57 million.
• Gross margin widened 0.9 percentage points to 63.5%, while operating income increased 13.3% to USD 18.51 million.
• Clinical Genomics revenue fell 3.6% to USD 45.39 million, while Biopharmaceutical Development was flat at USD 48.63 million.
• The company expects challenges in China to persist into fiscal 2027, with a substantially smaller financial impact than in fiscal 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000724004-26-000047), on June 03, 2026, and is solely responsible for the information contained therein.